BioGaia AB reports on study that shows Lactobacillus reuteri reduces bone loss in older women.
M2 EQUITYBITES-November 20, 2017-BioGaia AB reports on study that shows Lactobacillus reuteri reduces bone loss in older women
(C)2017 M2 COMMUNICATIONS http://www.m2.com
Swedish healthcare company BioGaia AB (STO: BIOGB) reported on Friday that a study has shown that Lactobacillus reuteri reduces bone loss in older women.
The company said a randomised, double-blind, placebo-controlled study in 90 older women showed that supplementation of the probiotic strain Lactobacillus reuteri ATCC PTA 6475 decreased bone loss, as compared to placebo.
Lactobacillus reuteri ATCC PTA 6475 is a naturally occurring bacteria in the gastrointestinal tract of humans and has been shown to have beneficial effects on bone in animals.
In this randomised controlled trial conducted at the University of Gothenburg, 75 to 80-year-old women with low bone density received supplementation of Lactobacillus reuteri ATCC PTA 6475 or placebo for one year.
In the group supplemented by Lactobacillus reuteri the loss in bone density was halved compared to placebo. Detailed results are expected to be published in a scientific journal.
According to the company, the fact that Lactobacillus reuteri ATCC PTA 6475 was shown to reduce bone loss in this group is very promising.
BioGaia develops, markets and sells probiotic products with documented health benefits.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Article Type:||Clinical report|
|Date:||Nov 20, 2017|
|Previous Article:||American Tower closes its acquisition of KIO Networks' urban telecommunications assets in Mexico for USD500m.|
|Next Article:||Marine Petroleum Trust to pay lower distribution of USD0.053238 per unit for Q4.|